1
|
Arraras J, Illarramendi J, Manterola-Burgaleta A, de la Cruz S, Zarandona U, Ibañez B, Salgado E, Visus I, Barrado M, Teijeira L, Martinez E, Vera R. Quality of Life of breast cancer patients with COVID-19 disease. Eur J Cancer 2022. [PMCID: PMC9671787 DOI: 10.1016/s0959-8049(22)01515-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Affiliation(s)
- J.I. Arraras
- Servicio Navarro de Salud/Complejo Hospitalario de Navarra, Oncology Departments, Pamplona, Spain
| | - J.J. Illarramendi
- Hospital Universitario de Navarra, Medical Oncology, Pamplona, Spain
| | | | - S. de la Cruz
- Hospital Universitario de Navarra, Medical Oncology, Pamplona, Spain
| | - U. Zarandona
- Hospital Universitario de Navarra, Oncology Departments, Pamplona, Spain
| | - B. Ibañez
- Navarrabiomed- Departamento de Salud-UPNA, Methodology, Pamplona, Spain
| | - E. Salgado
- Hospital Universitario de Navarra, Medical Oncology, Pamplona, Spain
| | - I. Visus
- Hospital Universitario de Navarra, Radiotherapeutic Oncology, Pamplona, Spain
| | - M. Barrado
- Hospital Universitario de Navarra, Radiotherapeutic Oncology, Pamplona, Spain
| | - L. Teijeira
- Hospital Universitario de Navarra, Medical Oncology, Pamplona, Spain
| | - E. Martinez
- Hospital Universitario de Navarra, Radiotherapeutic Oncology, Pamplona, Spain
| | - R. Vera
- Hospital Universitario de Navarra, Medical Oncology, Pamplona, Spain
| |
Collapse
|
2
|
Teng N, Dalby M, Kiu R, Robinson T, Gion Cortes M, Bermejo De Las Heras B, Perez Garcia J, Calvo-Martinez L, Prat A, Marquez Vazquez R, Ruiz Borrego M, de la Cruz S, Llombart Cussac A, Curigliano G, Schmid P, Mancino M, Hall L, Robinson S, Cortés J, Malfettone A. 14P Gut and oral microbiota profiling in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC) receiving pembrolizumab (P) plus eribulin (E): CALADRIO. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.03.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
3
|
Virizuela JA, Garcia AM, de las Peñas R, Santaballa A, Andrés R, Beato C, de la Cruz S, Gavilá J, González-Santiago S, Fernández TL. Replied to “Some remarks to SEOM clinical guidelines on cardiovascular toxicity (2018)”. Clin Transl Oncol 2019; 21:1788-1789. [DOI: 10.1007/s12094-019-02173-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2019] [Accepted: 06/28/2019] [Indexed: 11/30/2022]
|
4
|
Arraras JI, Illarramendi JJ, Manterola A, Asin G, Salgado E, Arrondo P, Dominguez MA, Arrazubi V, Martinez E, Viudez A, de la Cruz S, Vera R. Quality of life in elderly breast cancer patients with localized disease receiving endocrine treatment: a prospective study. Clin Transl Oncol 2019; 21:1231-1239. [PMID: 30712234 DOI: 10.1007/s12094-019-02048-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2018] [Accepted: 01/16/2019] [Indexed: 11/25/2022]
Abstract
PURPOSE In this paper we study the quality of life (QoL) of elderly breast cancer patients receiving endocrine treatment (ET). More QoL data on elderly patients treated with ET are needed. Our aims are to study QoL in early-stage breast cancer patients throughout the treatment period and compare the QoL of ET groups. METHODS 148 patients > 65 years who began ET with either tamoxifen or aromatase inhibitor (AI) completed the EORTC QLQ-C30 and QLQ-BR23 and the Interview for Deterioration in Daily Living Activities in Dementia (IDDD) questionnaires three times over 3 years of ET. Linear mixed-effect models were used to evaluate longitudinal QoL changes. ET group comparisons were conducted after 3 years of treatment via ANCOVA adjusted by basal QoL. RESULTS QoL scores were high (> 80/100 points) in most QoL areas, with moderate limitations (> 30) in sexual functioning and enjoyment and in future perspective. After 3 years of ET, four QoL areas improved (< 6 points) compared to baseline and 3-month assessments. Hot flushes worsened (8 points) at the 3-month assessment but by 3 years had recovered. AI patients showed more hot flushes, pain and diarrhea and less sexual enjoyment than tamoxifen patients after 3 years of ET (differences 3-12 points). CONCLUSIONS Results indicate that elderly early-stage breast cancer patients adapted well to their disease and ET treatment over the 3 years. Few QoL differences were observed between ET groups.
Collapse
Affiliation(s)
- J I Arraras
- Medical Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain. .,Radiotherapeutic Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain.
| | - J J Illarramendi
- Medical Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain
| | - A Manterola
- Radiotherapeutic Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain
| | - G Asin
- Radiotherapeutic Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain
| | - E Salgado
- Medical Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain
| | - P Arrondo
- Medical Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain.,Radiotherapeutic Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain
| | - M A Dominguez
- Radiotherapeutic Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain
| | - V Arrazubi
- Medical Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain
| | - E Martinez
- Radiotherapeutic Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain
| | - A Viudez
- Medical Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain
| | - S de la Cruz
- Medical Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain
| | - R Vera
- Medical Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain
| |
Collapse
|
5
|
Muñoz M, Santaballa A, Seguí MA, Beato C, de la Cruz S, Espinosa J, Fonseca PJ, Perez J, Quintanar T, Blasco A. SEOM Clinical Guideline of fertility preservation and reproduction in cancer patients (2016). Clin Transl Oncol 2016; 18:1229-1236. [PMID: 27896641 PMCID: PMC5138251 DOI: 10.1007/s12094-016-1587-9] [Citation(s) in RCA: 44] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2016] [Accepted: 11/16/2016] [Indexed: 11/30/2022]
Abstract
Chemotherapy and radiotherapy often result in reduced fertility in cancer patients. With increasing survival rates, fertility is an important quality-of-life concern for many young cancer patients. Around 70–75% of young cancer survivors are interested in parenthood but the numbers of patients who access fertility preservation techniques prior to treatment are significantly lower. Moreover, despite existing guidelines, healthcare professionals do not address fertility preservation issues adequately. There is a critical need for improvements in clinical care to ensure patients are well informed about infertility risks and fertility preservation options and to support them in their reproductive decision-making prior to cancer treatment.
Collapse
Affiliation(s)
- M Muñoz
- Servicio de Oncología Médica, Translational Genomics and Targeted Therapeutics in Solid Tumors, IDIBAPS, Hospital Clínic de Barcelona, Villarroel, 170-08036, Barcelona, Spain.
| | - A Santaballa
- Hospital Universitari I Politècnic la Fe, Valencia, Spain
| | - M A Seguí
- Corporació Sanitària Parc Taulì, Sabadell, Spain
| | - C Beato
- Hospital Universitario Virgen Macarena, Seville, Spain
| | - S de la Cruz
- Complejo Hospitalario de Navarra, Pamplona, Spain
| | - J Espinosa
- Hospital General de Ciudad Real, Ciudad Real, Spain
| | - P J Fonseca
- Hospital Universitario Central de Asturias, Oviedo, Spain
| | - J Perez
- Hospital General Universitario de Elche y Vega Baja, Elche, Spain
| | - T Quintanar
- Hospital General Universitario de Elche y Vega Baja, Elche, Spain
| | - A Blasco
- Hospital General Universitario de Valencia, Valencia, Spain
| |
Collapse
|
6
|
Arraras JI, Illarramendi JJ, de la Cruz S, Asin G, Manterola A, Ibanez B, Salgado E, Cambra K, Zarandona U, Dominguez MA, Vera R. Erratum:Quality of life in long-term premenopausal early-stage breast cancer survivors from Spain. Effects of surgery and time since surgery. J BUON 2016; 21:1573. [PMID: 28039732] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
In this article published in Volume 21, issue 5, the authors' names were incorrectly stated in the Pubmed abstract as: "Ignacio Arraras J(1), Juan Illarramendi J, de la Cruz S, Asin G, Manterola A, Ibanez B, Salgado E, Cambra K, Zarandona U, Angel Dominguez M, Vera R.". The correct authors' names are: "Arraras JI(1), Illarramendi JJ, de la Cruz S, Asin G, Manterola A, Ibanez B, Salgado E, Cambra K, Zarandona U, Dominguez MA, Vera R.". This error appeared only in the PubMed database and not in the print form of the Journal.
Collapse
Affiliation(s)
- J I Arraras
- Complejo Hospitalario de Navarra, Department of Medical Oncology, Pamplona, Spain
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Espinós J, Reyna C, de la Cruz S, Oiler C, Hernández A, Fernández Hidalgo O, Santisteban M, García Foncillas J. [Hormonal therapy in breast cancer]. Rev Med Univ Navarra 2008; 52:40-48. [PMID: 18578196] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
Hormonal therapy has been the first systemic treatment against breast cancer. Up to now Tamoxifen and ovarian supression/ablation were the best optionts we had to treat early breast cancer as advancer disease. The advent of aromatase inhibitors, new SERMS and antistrogen Fulvestrant have supoused a great advance in the treatment of this disease and at the same time have complicated the election of the optimal drug for each patient. This article tries to review the aviable treatment options insiting on its indications.
Collapse
Affiliation(s)
- J Espinós
- Area de tumores ginecológicos y de mama, Departamento de Oncología, Clínica Universitaria, Facultad de Medicina. Universidad de Navarra, Pamploma.
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Gil-Bazo I, Rodríguez J, Catalán V, Alonso A, de la Cámara J, de la Cruz S, Viteri S, Sola JJ, Hernández-Lizoáin JL, García-Foncillas J. Preoperative angiogenesis and clotting/fibrinolysis circulating factors correlate with tumor stage, p21 and c-myc in colorectal cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3699] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | - A. Alonso
- Clin Univ de Navarra, Pamplona, Spain
| | | | | | - S. Viteri
- Clin Univ de Navarra, Pamplona, Spain
| | | | | | | |
Collapse
|
9
|
Espinos Jimenez J, Lopez-Picazo JM, Moreno Jimenez M, Chopitea A, de la Camara J, de la Cruz S, Garcia-Foncillas J, Martin-Algarra S, Perez Gracia JL, Gurpide Ayarra A. Short induction docetaxel, doxorubicin, cisplatin and methotrexate followed by concurrent chemoradiation for nasopharyngeal carcinoma (NPC). A pilot study. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.5590] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
10
|
|
11
|
Alcaraz VM, Castro-Velázquez I, de la Cruz S, del Valle G. Conditioning and recovery of functions lost by brain damage. Neurosci Biobehav Rev 1981; 5:371-83. [PMID: 7301223 DOI: 10.1016/0149-7634(81)90031-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
The muscle spindle is a receptor apparatus in striated muscle that is necessary for voluntary muscle movement. Paralysis victims lose the feedback of this receptor and cannot initiate motor responses. Four hemiplegic patients were trained to use auditory feedback from electromyographic recordings to initiate activity in paretic limbs. With the addition of visual feedback and the use of the auditory signal as a reinforcing stimulus, the patients' muscle activity was then shaped to approximate normal movement.
Collapse
|
12
|
Abstract
In a 4-week double-blind trial in 41 patients with rheumatoid arthritis, ibuprofen (Motrin) decreased the swollen joint count significantly at a dosage level of 2400 mg/day, but not at 1200 mg/day. Ibuprofen probably does have antiinflammatory effects in man, but only at higher dosages; antiarthritic activity at lower dosages reflects primarily analgesia and perhaps antipyretic effects. Complaints and clinical laboratory findings did not differ significantly between the dosage groups.
Collapse
|